Abstract 292P
Background
Cervical cancer is the second most common malignancy among women in poor countries, according to the World Health Organization. According to some writers, cervical cancer is the second- or third-leading cause of mortality for women over 30 in Uzbekistan. Statistics on cervical cancer are hotly debated because not all women visit a doctor. On the pathologist's table, the diagnosis is frequently made.
Methods
During a regular checkup, 92 women between the ages of 25 and 48 were seen at the antenatal clinic of hospital No. 1g. Using liquid cytology and Pap test technologies, a screening cytological examination was performed on all women. According to clinical recommendations, the PAP test classes were interpreted as follows: class 1 — normal; class 2 — inflammatory type; class 3 — dyskaryosis; class 4 — cells suggestive for cancer or carcinoma; and class 5 — malignancy.
Results
50 women had normal cytological screening results from Pap tests, while 36 had inflammatory type outcomes. There was an inadequate type of sample in 6 women. A negative result of cytological screening by liquid cytology was found in 44 women; 36 women had cytograms that were within the normal range; and 10 women had atypical cells of stratified squamous epithelium that were of unknown significance. Additionally, 2 women developed epithelial squamous lesions of low severity. Compared to liquid cytology, which had a sensitivity of 77.0%, the Pap test had a sensitivity of 33.0%. While liquid cytology had a specificity of 72.0%, the Pap test had a higher specificity of 87.0%. Liquid cytology and the predictive value of a positive Pap test were comparable. Compared to the PAP test, the liquid cytology test had a better predictive value for a negative outcome.
Conclusions
The study's findings revealed that both approaches to early cervical cancer diagnosis estimate the incidence of the condition equally. In addition, liquid cytology makes it more probable to produce a positive result in the group of patients who actually have the disease and, to a lesser extent, in those who do not. When employing the liquid cytology method, the prognosis of the likelihood of the disease being absent in patients with a negative result was higher.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract